Effects of ABCB1 DNA methylation in donors on tacrolimus blood concentrations in recipients following liver transplantation

To investigate the effects of ABCB1 DNA methylation in donors on individual differences in tacrolimus blood concentrations following liver transplantation.

[1]  Yang Xu,et al.  Downregulation of CYP2E1 is associated with poor prognosis and tumor progression of gliomas , 2021, Cancer medicine.

[2]  C. George Priya Doss,et al.  Computational validation of ABCB1 gene polymorphism and its effect on tacrolimus dose concentration/levels in renal transplant individuals of South India , 2021, Comput. Biol. Medicine.

[3]  F. Costa,et al.  Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. , 2021, Chemico-biological interactions.

[4]  Liwen Zhang,et al.  The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients , 2021, Pharmacological Reports.

[5]  Liyan Xu,et al.  Combined influence of ABCB1 genetic polymorphism and DNA methylation on aspirin resistance in Chinese ischemic stroke patients , 2021, Acta Neurologica Belgica.

[6]  Fangzhou Song,et al.  Identification of genetic variations associated with drug resistance in non-small cell lung cancer patients undergoing systemic treatment , 2021, Briefings Bioinform..

[7]  G. Russ,et al.  Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients , 2021, British journal of clinical pharmacology.

[8]  F. Azam,et al.  Influence of ABCB1 gene polymorphism on concentration to dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients , 2021, Pakistan journal of medical sciences.

[9]  T. Efferth,et al.  Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy in vitro and in vivo , 2021, Acta pharmaceutica Sinica. B.

[10]  I. A. D. de Graaf,et al.  Postnatal Smoke Exposure Further Increases the Hepatic Nicotine Metabolism in Prenatally Smoke Exposed Male Offspring and Is Linked with Aberrant Cyp2a5 Methylation , 2020, International journal of molecular sciences.

[11]  K. Monostory,et al.  Clinical significance of personalized tacrolimus dosing by adjusting to donor CYP3A‐status in liver transplant recipients , 2020, British journal of clinical pharmacology.

[12]  Yang Lin,et al.  Effect of ABCB1 3435C>T Genetic Polymorphism on Pharmacokinetic Variables of Tacrolimus in Adult Renal Transplant Recipients: a Systematic Review and Meta-analysis. , 2020, Clinical therapeutics.

[13]  Huifen Zhang,et al.  Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms , 2020, European Journal of Clinical Pharmacology.

[14]  Lirong Zhang,et al.  DNA methylation determines the regulation of pregnane X receptor on CYP3A4 expression , 2020, Clinical and experimental pharmacology & physiology.

[15]  Jing‐Yan Han,et al.  Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles , 2020, Nature Biomedical Engineering.

[16]  L. Jonaitis,et al.  Role of Genetic Polymorphisms of Cytochrome P450 2C19 in Pantoprazole Metabolism and Pantoprazole-based Helicobacter pylori Eradication Regimens. , 2020, Current drug metabolism.

[17]  J. McClay,et al.  DNA methylation and histone acetylation changes to cytochrome P450 2E1 regulation in normal aging and impact on rates of drug metabolism in the liver , 2020, GeroScience.

[18]  X. Zhan,et al.  MASS SPECTROMETRY-BASED PERSONALIZED DRUG THERAPY. , 2020, Mass spectrometry reviews.

[19]  E. Çolak,et al.  Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients. , 2019, Clinical laboratory.

[20]  Yitian Zhou,et al.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity , 2019, Pharmacology & therapeutics.

[21]  U. Christians,et al.  Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report , 2019, Therapeutic drug monitoring.

[22]  P. Marquet,et al.  A donor and recipient candidate gene association study of allograft loss in renal transplant recipients receiving a tacrolimus‐based regimen , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  Dexi Chen,et al.  Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients , 2018, International immunopharmacology.

[24]  Shusen Sun,et al.  Association of ABCB1 promoter methylation with aspirin exposure, platelet function, and clinical outcomes in Chinese intracranial artery stenosis patients , 2017, European Journal of Clinical Pharmacology.

[25]  Hang He,et al.  [Effects of pargyline on histone methylation in promoter and enhancer regions and transcription of CYP3A4/3A7]. , 2017, Yao xue xue bao = Acta pharmaceutica Sinica.

[26]  Y. Li,et al.  Combined Influence of Genetic Polymorphism and DNA Methylation on ABCB1 Expression and Function in Healthy Chinese Males , 2017, European journal of drug metabolism and pharmacokinetics.

[27]  Min Chang Kim,et al.  Monitoring the Intracellular Tacrolimus Concentration in Kidney Transplant Recipients with Stable Graft Function , 2016, PloS one.

[28]  Y. Li,et al.  Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects. , 2015, British journal of clinical pharmacology.

[29]  A. Mencalha,et al.  ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter , 2014, Epigenetics.

[30]  H. Bi,et al.  Effect of Tacrolimus on the pharmacokinetics of bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) and the potential roles of CYP3A and P-gp. , 2014, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[31]  K. Oka,et al.  Decitabine, a DNA methyltransferase inhibitor, reduces P-glycoprotein mRNA and protein expressions and increases drug sensitivity in drug-resistant MOLT4 and Jurkat cell lines. , 2012, Anticancer research.

[32]  Yan Jiang,et al.  Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. , 2011, Annals of transplantation.

[33]  G. Wakabayashi,et al.  CYP1B1, but not CYP1A1, is downregulated by promoter methylation in colorectal cancers. , 2009, International journal of oncology.

[34]  V. Haufroid,et al.  Validation of a Liquid Chromatography-Mass Spectrometric Assay for Tacrolimus in Peripheral Blood Mononuclear Cells , 2009, Therapeutic drug monitoring.

[35]  S. Masuda,et al.  Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living‐donor liver transplant patients , 2006, Clinical pharmacology and therapeutics.

[36]  M. Nakajima,et al.  Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7 and HeLa cells. , 2003, Toxicology letters.